eylea
NICE Macular Oedema (Branch Retinal Vein Occlusion) Final Technology Appraisal
Response to NICE announcing their positive final guidance for Eylea® for the treatment of adult patients with visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO) The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea (aflibercept) as a first-line treatment option for patients with visual
NICE announce positive final guidance for Eylea® for the treatment of macular oedema secondary to CRVO
College Statement In response to NICE announcing their positive final guidance for Eylea® for the treatment of macular oedema secondary to CRVO The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea® (aflibercept) as a treatment option for visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
Response to NICE announcing their positive draft guidance for Eylea® for the treatment of macular oedema secondary to CRVO
College Statement The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea® (aflibercept) as a treatment option for visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). We hope that this decision will help the clinical commissioning groups to support the rapid implementation of the final
Positive draft final guidance from NICE for Eylea® for the treatment on wet AMD
College Statement The Royal College of Ophthalmologists welcomes the NICE draft final guidance which announces that Eylea® (aflibercept) should be recommended for the treatment of patients with wet age-related macular degeneration (wAMD). Eylea® is a soluble vascular endothelial growth factor (VEGF) receptor fusion protein which binds to all forms of VEGF and placental growth factor
Response to SMC Decision to accept Eylea for wet AMD
Statement from The Royal College of Ophthalmologists The Royal College of Ophthalmologists welcomes the SMC decision to recommend Aflibercept (Eylea®) as a treatment for neovascular AMD. Aflibercept is a soluble vascular endothelial growth factor (VEGF) receptor fusion protein which binds to all forms of VEGF and inhibits its actions. This drug has been shown in